Search results for "VANCOMYCIN"

showing 10 items of 69 documents

Gut Microbiota Condition the Therapeutic Efficacy of Trastuzumab in HER2-Positive Breast Cancer.

2021

Abstract Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclinical models of HER2-positive breast cancer and in 24 patients with primary HER2-positive breast cancer undergoing trastuzumab-containing neoadjuvant treatment. In mice, the antitumor activity of trastuzumab was impaired by antibiotic administration or fecal microbiota transplantation from antibiotic-treated donors. Modulation of the intestinal microbiota was reflected in tumors by impaired recruitment of CD4+ T cells and granzyme B–posi…

0301 basic medicineCD4-Positive T-LymphocytesCancer ResearchReceptor ErbB-2medicine.medical_treatmentGut floraGranzymesMice0302 clinical medicineAntineoplastic Agents ImmunologicalTrastuzumabTumor Microenvironmentskin and connective tissue diseasesNeoadjuvant therapybiologyFecal Microbiota TransplantationInterleukin-12Neoadjuvant TherapyAnti-Bacterial AgentsTreatment OutcomeOncology030220 oncology & carcinogenesisStreptomycinCytokinesGut microbiota trastuzumab breast cancerFemaleTaxoidsmedicine.drugBridged-Ring CompoundsBreast NeoplasmsSettore MED/08 - Anatomia PatologicaNitric Oxide03 medical and health sciencesImmune systemBreast cancerVancomycinmedicineAnimalsHumansCyclophosphamideImmunity Mucosalbusiness.industryLachnospiraceaeDendritic cellDendritic CellsTrastuzumabbiology.organism_classificationmedicine.diseaseGastrointestinal Microbiome030104 developmental biologyGranzymeDoxorubicinImmune Systembiology.proteinCancer researchInterferonsbusinessCancer research
researchProduct

What happens in hospitals does not stay in hospitals: antibiotic-resistant bacteria in hospital wastewater systems.

2016

Hospitals are hotspots for antimicrobial-resistant bacteria (ARB) and play a major role in both their emergence and spread. Large numbers of these ARB will be ejected from hospitals via wastewater systems. In this review, we present quantitative and qualitative data of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli, vancomycin-resistant enterococci and Pseudomonas aeruginosa in hospital wastewaters compared to community wastewaters. We also discuss the fate of these ARB in wastewater treatment plants and in the downstream environment. Published studies have shown that hospital effluents contain ARB, the burden of these bacteria being dependent on their local prevalence. The…

0301 basic medicineMicrobiology (medical)030106 microbiologyWastewater010501 environmental sciencesurologic and male genital diseasesmedicine.disease_cause01 natural sciencesbeta-LactamasesVancomycin-Resistant EnterococciWater Purification03 medical and health sciencesAntibiotic resistance[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance BacterialEscherichia colimedicineHumansVancomycin-resistant EnterococcusSelection GeneticEffluentComputingMilieux_MISCELLANEOUS0105 earth and related environmental sciencesPseudomonas aeruginosabusiness.industryGeneral MedicineAntimicrobialHospitals6. Clean waterAnti-Bacterial Agents3. Good healthBiotechnologyMultiple drug resistanceInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyWastewater13. Climate actionPseudomonas aeruginosaSewage treatmentbusiness
researchProduct

No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia

2018

International audience; The vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia. In this study, the outcomes of patients with MSSA bacteraemia with a vancomycin MIC ≥ 1.5 mg/L were assessed. A prospective cohort of patients with MSSA bacteraemia in two tertiary-care hospitals was collected. The vancomycin MIC was determined by Etest. Staphylococcus aureus strains were categorised as low (<1.5 mg/L) or high (≥1.5 mg/L) vancomycin MIC. First- and second-line treatments were recorded and classified as optimal, appropriate and inappropriate. The primary endpoint was 30-day mortality. A total o…

0301 basic medicineMicrobiology (medical)MaleMethicillin-Resistant Staphylococcus aureusmedicine.medical_specialtyStaphylococcus aureusmedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticsBacteremiaMicrobial Sensitivity Testsmedicine.disease_cause03 medical and health sciencesMinimum inhibitory concentrationVancomycin[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInternal medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologymedicineHumansPharmacology (medical)Prospective StudiesMortalityProspective cohort studyEtestDialysisAgedAged 80 and overMinimum inhibitory concentrationbusiness.industryGeneral MedicineMiddle AgedStaphylococcal Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycoses3. Good healthAnti-Bacterial Agents[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesStaphylococcus aureusCatheter-Related InfectionsVancomycinBacteraemiaFemaleMethicillin Susceptible Staphylococcus Aureusbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Factors associated with 12 week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study

2016

International audience; Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialtyStaphylococcus aureusmedicine.drug_class030106 microbiologyAntibioticsBacteremiaPenicillinsPrognostic factorsTertiary Care Centers03 medical and health sciencesInterquartile range[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinInternal medicineCase fatality ratemedicineHumansBlood cultureProspective StudiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedAntistaphylococcal penicillinsCross Infectionmedicine.diagnostic_testbusiness.industrySeptic shockGeneral MedicineMiddle AgedStaphylococcal Infectionsmedicine.diseasePrognosisSurvival Analysis3. Good healthSurgeryInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyVancomycinBacteraemiaAntistaphylococcal penicillinFemaleFrancebusinessmedicine.drug
researchProduct

High vancomycin MICs within the susceptible range in Staphylococcus aureus bacteraemia isolates are associated with increased cell wall thickness and…

2016

Vancomycin minimum inhibitory concentrations (MICs) at the upper end of the susceptible range for Staphylococcus aureus have been associated with poor clinical outcomes of bloodstream infections. We tested the hypothesis that high vancomycin MICs in S. aureus bacteraemia isolates are associated with increased cell wall thickness and suboptimal bacterial internalisation or lysis by human phagocytes. In total, 95 isolates were evaluated. Original vancomycin MICs were determined by Etest. The susceptibility of S. aureus isolates to killing by phagocytes was assessed in a human whole blood assay. Internalisation of bacterial cells by phagocytes was investigated by flow cytometry. Cell wall thic…

0301 basic medicineMicrobiology (medical)Staphylococcus aureusLysisGenotyping Techniques030106 microbiologyBacteremiaMicrobial Sensitivity TestsBiologymedicine.disease_causeStaphylococcal infectionsMicrobiologyFlow cytometry03 medical and health sciences0302 clinical medicineCell WallVancomycinmedicineHumansPharmacology (medical)030212 general & internal medicineMinimum inhibitory concentration (MIC)EtestPhagocytesCell wall thicknessMicrobial Viabilitymedicine.diagnostic_testGeneral MedicineHuman phagocytesStaphylococcal InfectionsFlow CytometryMicroarray Analysismedicine.diseaseEndocytosisAnti-Bacterial AgentsIntracellular killingInfectious DiseasesStaphylococcus aureusBacteremiaVancomycinIntracellularmedicine.drugInternational Journal of Antimicrobial Agents
researchProduct

Complex Regulatory Networks Governing Production of the Glycopeptide A40926

2018

Glycopeptides (GPAs) are an important class of antibiotics, with vancomycin and teicoplanin being used in the last 40 years as drugs of last resort to treat infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. A few new GPAs have since reached the market. One of them is dalbavancin, a derivative of A40926 produced by the actinomycete Nonomuraea sp. ATCC 39727, recently classified as N. gerenzanensis. This review summarizes what we currently know on the multilevel regulatory processes governing production of the glycopeptide A40926 and the different approaches used to increase antibiotic yields. Some nutrients, e.g., valine, l-glutamine and mal…

0301 basic medicineMicrobiology (medical)medicine.drug_class030106 microbiologyAntibioticsInfectious DiseaseReviewGlycopeptide antibioticBiologyLuxR solomedicine.disease_causeBiochemistryMicrobiologyMicrobiology03 medical and health sciencesStrRValinemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsA40926Regulatory geneRegulator geneTeicoplaninlcsh:RM1-950DalbavancinLALA40926; Dalbavancin; Dbv cluster; Glycopeptide antibiotics; LAL; LuxR solo; Regulatory genes; StrR; Microbiology; Biochemistry; Pharmacology Toxicology and Pharmaceutics (all); Microbiology (medical); Infectious Diseases; Pharmacology (medical)regulatory genesGlycopeptidelcsh:Therapeutics. PharmacologyInfectious DiseasesDalbavancinStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Dbv clusterVancomycinglycopeptide antibioticsmedicine.drugAntibiotics
researchProduct

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

2019

Abstract Objectives In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates. Methods A ‘meta-model’ with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0–24 of 400 mg·h/L at steady-state in at least 80% of neonates. Results A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if &lt…

0301 basic medicinePediatricsvancomycininfusion procedures0302 clinical medicinenewbornMedicinePharmacology (medical)Randomized Controlled Trials as Topiceducation.field_of_studyMaintenance doseAnti-Bacterial Agents3. Good healthInfectious Diseasesdrug maintenance doseResearch DesignArea Under CurveData Interpretation Statisticalcreatinine testsVancomycinMonte Carlo Methodmedicine.drugMicrobiology (medical)medicine.medical_specialty030106 microbiologyPopulationGestational AgeMicrobial Sensitivity TestsLoading doseRS03 medical and health sciencesPharmacokineticsdrug loading dose030225 pediatricsHumanssteady stateeducationPharmacologyDose-Response Relationship Drugbusiness.industryBody WeightInfant NewbornPostmenstrual AgeinfantNONMEMRegimen[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieregimen[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessserum
researchProduct

Identification and structural characterization of LytU, a unique peptidoglycan endopeptidase from the lysostaphin family

2017

AbstractWe introduce LytU, a short member of the lysostaphin family of zinc-dependent pentaglycine endopeptidases. It is a potential antimicrobial agent for S. aureus infections and its gene transcription is highly upregulated upon antibiotic treatments along with other genes involved in cell wall synthesis. We found this enzyme to be responsible for the opening of the cell wall peptidoglycan layer during cell divisions in S. aureus. LytU is anchored in the plasma membrane with the active part residing in the periplasmic space. It has a unique Ile/Lys insertion at position 151 that resides in the catalytic site-neighbouring loop and is vital for the enzymatic activity but not affecting the …

0301 basic medicineentsyymitantimicrobial compoundsPROTEINchemistry.chemical_compoundCatalytic DomainCELL-WALLBINDINGMultidisciplinaryACTIVE-SITEQRESISTANT STAPHYLOCOCCUS-AUREUSRHydrogen-Ion ConcentrationAnti-Bacterial AgentsZincBiochemistryMedicineHISTIDINESProtein BindingStaphylococcus aureusScienceenzymesBiologyCleavage (embryo)metalloproteinasesArticleCofactorBACILLUS-SUBTILISCell wallStructure-Activity Relationship03 medical and health sciencesEndopeptidasesProtein Interaction Domains and MotifsAmino Acid Sequencestaphylococciantimikrobiset yhdisteetBinding SitesLysostaphinCell MembraneActive siteIsothermal titration calorimetryPeriplasmic spaceVANCOMYCINstafylokokitmetalloproteinaasitMODEL030104 developmental biologyRESOLUTIONchemistryMutationProteolysisLysostaphinbiology.protein1182 Biochemistry cell and molecular biologyPeptidoglycanScientific Reports
researchProduct

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct

Vancomycin resistant Enterococcus faecium (VRE) vertebral osteomyelitis after uneventful spinal surgery: A case report and literature review

2017

Abstract Objective Case report and literature review. Background Enterococcus faecium is an emerging pathogen responsible for post procedural infections in patients who have undergone spinal decompression surgery. In this case report, the authors discuss and review recent literature on approaches to post-operative spinal infection. Case report We herein report the case of a 55-year-old HIV-negative Caucasian Italian woman who showed vertebral osteomyelitis with abscesses around the interbody cage caused by an Enterococcus faecium vancomycin resistant gen-Van A, following a Transforaminal Lumbar Interbody Fusion (TLIF). The same strain was detected in disc biopsy, urine culture and rectal sw…

0301 basic medicinemedicine.medical_specialtySettore MED/07 - Microbiologia E Microbiologia ClinicaEnterococcus faecium; Spinal surgery; Transforaminal Lumbar Interbody Fusion (TLIF); Vertebral osteomyelitis; Surgery; Neurology (clinical)Settore MED/17 - Malattie Infettive030106 microbiologyEnterococcus faeciumlcsh:Surgerylcsh:RC346-42903 medical and health sciencesEmerging pathogen0302 clinical medicineAntibiotic resistanceVertebral osteomyelitisBiopsymedicineVertebral osteomyelitislcsh:Neurology. Diseases of the nervous systemVancomycin resistant Enterococcus faeciumTransforaminal Lumbar Interbody Fusion (TLIF)medicine.diagnostic_testbiologybusiness.industrySettore MED/27 - Neurochirurgialcsh:RD1-811biology.organism_classificationmedicine.diseaseSpinal surgerySurgerySurgeryImplantSpinal surgeryNeurology (clinical)Vertebral osteomyelitibusiness030217 neurology & neurosurgeryEnterococcus faeciumInterdisciplinary Neurosurgery
researchProduct